GlassScriptPhysician profile
Raman N Gopalakrishnan
NPI 1982688271
$10,792.27
in general payments reported to CMS, 2019-2025
30 companies · $2,403 in 2025
The $2,403 reported for 2025 was more than what 91% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $234 · 2020: $512 · 2021: $1,316 · 2022: $1,657 · 2023: $2,170 · 2024: $2,500 · 2025: $2,403.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,959 · Education: $114.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,958.92 |
| Education | $113.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,482.30 | 2021-2025 | Caplyta |
| Abbvie INC. | $1,269.05 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $1,159.12 | 2020-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $1,123.16 | 2020-2025 | Abilify Mycite, Rexulti, Abilify Maintena |
| Alkermes, INC. | $860.23 | 2019-2025 | Aristada, Lybalvi, Vivitrol |
| Axsome Therapeutics, INC. | $814.01 | 2022-2025 | Auvelity, Sunosi |
| Teva Pharmaceuticals USA, INC. | $525.67 | 2019-2025 | Austedo, Austedo Xr, Austedo Xr |
| Corium, LLC | $486.84 | 2022-2025 | Azstarys |
| Lundbeck LLC | $484.98 | 2020-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $449.25 | 2020-2025 | Trintellix |
| Vanda Pharmaceuticals INC. | $322.57 | 2019-2025 | Fanapt, Hetlioz |
| Allergan, INC. | $291.54 | 2019-2020 | |
| Bausch Health US, LLC | $218.20 | 2022-2025 | Aplenzin, Wellbutrin |
| Sunovion Pharmaceuticals INC. | $211.57 | 2020-2021 | |
| Almatica Pharma LLC | $193.79 | 2024-2025 | Loreev Xr |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $171.88 | 2021-2025 | Invega Sustenna, Invega Trinza, Invega |
| Idorsia Pharmaceuticals US INC | $125.59 | 2022-2024 | Quviviq |
| Ironshore Pharmaceuticals INC. | $117.06 | 2022-2023 | Jornay Pm |
| Merck Sharp & Dohme LLC | $115.95 | 2021-2023 | Belsomra |
| Avanir Pharmaceuticals, INC. | $64.95 | 2021-2022 | |
| Lilly USA, LLC | $62.63 | 2022-2024 | Amyvid |
| Noven Therapeutics, LLC | $61.07 | 2021-2024 | Xelstrym, Secuado |
| Eisai INC. | $35.30 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $32.26 | 2025 | Cobenfy |
| Biogen, INC. | $23.89 | 2022 | |
| Jazz Pharmaceuticals INC. | $21.67 | 2022 | |
| Owp Pharmaceuticals, INC. | $19.61 | 2022 | |
| Neos Therapeutics, LP | $18.93 | 2024 | Adzenys Xr-Odt |
| Neuronetics, INC. | $15.00 | 2021 | |
| Vertical Pharmaceuticals, LLC | $14.20 | 2025 | Relexxii |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raman Gopalakrishnan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.